(Q38095611)

28 August 2017

title

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers (English)

1 reference

28 August 2017

4

Anne E Kiltie

1 reference

28 August 2017

Naomi L Sharma

1

1 reference

28 August 2017

Blaz Groselj

series ordinal

2

1 reference

28 August 2017

Freddie C Hamdy

series ordinal

3

1 reference

28 August 2017

publication date

1 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

111

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

537-542

1 reference

Inhibition of bladder tumour growth by histone deacetylase inhibitor

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Histone deacetylase and DNA methyltransferase in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Modulation of radiation response by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11647.X

10.1111/J.1464-410X.2012.11647.X

21 January 2018

Identifiers

DOI

1 reference

release_k72w7fvp4zajzgeam7o2uiie6q

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k72w7fvp4zajzgeam7o2uiie6q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference